9,185
Total Claims
$1.0M
Drug Cost
499
Beneficiaries
$2,033
Cost/Patient
Peer Comparison vs. 110,156 Internal Medicine providers
+44%
Cost per patient vs peers
$2,033 vs $1,411 avg
+34%
Brand preference vs peers
14.3% vs 10.6% avg
Brand vs Generic
86% generic
Brand: 1,295 claims · $870K
Generic: 7,771 claims · $138K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 103 | $112K |
| Empagliflozin | 129 | $109K |
| Semaglutide | 88 | $106K |
| Sitagliptin Phosphate | 71 | $67K |
| Budesonide/Formoterol Fumarate | 58 | $36K |
| Insulin Detemir | 33 | $26K |
| Rivaroxaban | 21 | $24K |
| Canagliflozin | 23 | $23K |
| Linagliptin | 20 | $22K |
| Tiotropium Bromide | 34 | $22K |
| Insulin Aspart | 21 | $21K |
| Empagliflozin/Metformin Hcl | 18 | $20K |
| Dulaglutide | 12 | $18K |
| Insulin Glargine,hum.Rec.Anlog | 40 | $17K |
| Linaclotide | 22 | $16K |
Prescribing Profile
Patient Profile
76
Avg Age
78%
Female
1.18
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data